Encyclopedia of Heart Diseases

2011 Edition
| Editors: M. Gabriel Khan

Antiplatelet Agents

Reference work entry
DOI: https://doi.org/10.1007/978-1-60761-219-3_16

Overview

Aspirin was the only antiplatelet agent available from the 1970s to the 1980s. Several agonists including thromboxane A 2 (TXA 2), adenosine diphosphate (ADP), thrombin, serotonin, epinephrine, and collagen can activate the  platelet and provide the essentials for thrombosis to occur. Aspirin inhibits the production of thromboxane A 2, a powerful platelet-aggregating agent, by its effect on the enzyme cyclooxygenase (COX). Over the past 2 decades, the appropriate use of aspirin, clopidogrel, and platelet glyco protein receptor blockers has improved mortality and morbidity in patients with coronary artery disease (CAD).
  • Two agents, ticagrelor and prasugrel, have been added to the therapeutic armamentarium, and hope prevails.

These cardioactive drugs are useful in the prevention of  thrombi in coronary arteries and those arteries that supply the brain, but they are much less effective in preventing thrombi that occur in veins. They are beneficial in the treatment of acute  myocardi...

This is a preview of subscription content, log in to check access.

Bibliography

References

  1. Ben-Yehuda O (2006) Editorial comment: upstream/downstream glycoprotein IIb/IIIa in non–ST-segment elevation myocardial infarction. J Am Coll Cardiol 47:538–540PubMedGoogle Scholar
  2. Björkman J-A, Kirk I, van Giezen JJ (2007) AZD6140 inhibits adenosine uptake into erythrocytes and enhances coronary blood flow after local ischemia or intracoronary adenosine infusion. Circulation 116 (Suppl II): II–28. (abstr). PubMedGoogle Scholar
  3. Bliden KP, DiChiara J, Lawal L et al (2008) The association of cigarette smoking with enhanced platelet inhibition by clopidogrel. J Am Coll Cardiol 52:531–533. doi:10.1016/j.jacc.2008.04.045PubMedGoogle Scholar
  4. Brar SS, Kim J, Brar SK et al (2008) Long-term outcomes by clopidogrel duration and stent type in a diabetic population with de novo coronary artery lesions. J Am Coll Cardiol 51:2220–2227PubMedGoogle Scholar
  5. Cairns JA, Gent M, Singer J et al (1986) Aspirin, sulfinpyrazone or both in unstable angina. N Engl J Med 313:1369Google Scholar
  6. Canadian Cooperative Study Group (1978) A randomized trial of aspirin and sulfinpyrazone in threatened stroke. N Engl J Med 299:53Google Scholar
  7. Choi S-H, Prasad A, Tsimikas S (2008) The evolution of thienopyridine therapy, clopidogrel duration, diabetes, and drug-eluting stents. J Am Coll Cardiol 51:2228–2229PubMedGoogle Scholar
  8. Coller BS (1995) Blockade of platelet GP IIb/IIIa receptors as an antithrombotic strategy. Circulation 92:2373–2380PubMedGoogle Scholar
  9. Cox D, Maree AO, Dooley M et al (2006) Effect of enteric coating on antiplatelet activity of low-dose aspirin in healthy volunteers. Stroke 37:2153–2158PubMedGoogle Scholar
  10. Craven LL (1953) Experiences with aspirin (acetylsalicylic acid) in the non-specific prophylaxis of coronary thrombosis. Miss Valley Med J 75:38PubMedGoogle Scholar
  11. Davies MJ, Thomas A (1984) Thrombosis and acute coronary artery lesions in sudden cardiac ischemic death. N Engl J Med 310:1137PubMedGoogle Scholar
  12. Desai NR, Mega JL, Jiang S et al (2009) Interaction between cigarette smoking and clinical benefit of clopidogrel. J Am Coll Cardiol 53:1273–1278PubMedGoogle Scholar
  13. DeWood MA, Spores J, Notske R et al (1980) Prevalence of total coronary occlusion during the early hours of transmural myocardial infarction. N Engl J Med 303:897PubMedGoogle Scholar
  14. Elwood PC, Cochrane AL, Burr ML et al (1974) A randomized controlled trial of acetylsalicylic acid in the secondary prevention of mortality from myocardial infarction. BMJ 1:436PubMedGoogle Scholar
  15. Fields WS, Lemak NA, Frankowski RF et al (1977) Controlled trial of aspirin in cerebral ischemia. Stroke 8:301PubMedGoogle Scholar
  16. Gasparyan AY, Watson T, Lip GY (2008) The role of aspirin in cardiovascular prevention: implications of aspirin resistance. J Am Coll Cardiol 51:1829–1843PubMedGoogle Scholar
  17. Gurbel PA, Bliden KP, Butler K et al (2009) Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study. Circulation 120:2577–2585PubMedGoogle Scholar
  18. Ho PM, Maddox TM, Li Wang F et al (2009) Risk of adverse outcomes associated with concomitant use of clopidogrel and proton pump inhibitors following acute coronary syndrome. JAMA 301(9):937–944PubMedGoogle Scholar
  19. Juul-Moller S, Edvardsson N, Jhnmatz B et al (1992) Double-blind trial of aspirin in primary prevention of myocardial infarction in patients with stable chronic angina pectoris. Lancet 340:1421PubMedGoogle Scholar
  20. Kapoor JR (2008) Enteric coating is a possible cause of aspirin resistance. J Am Coll Cardiol 52:1276–1277. doi:10.1016/j.jaccPubMedGoogle Scholar
  21. Khan M Gabriel (2007) Antiplatelet agents. In Cardiac Drug Therapy, 7th edn. Humana Press, New YorkGoogle Scholar
  22. Kleiman NS (2008) Clopidogrel and calcium-channel antagonists: another drug–drug interaction for the ever-wary clinician? J Am Coll Cardiol 52:1564–1566PubMedGoogle Scholar
  23. Lev EI, Patel RT, Maresh KJ (2006) The role of dual drug resistance. J Am Coll Cardiol 47:27–33PubMedGoogle Scholar
  24. Lewis HD, Davis JW, Archibald DG et al (1983) Protective effects of aspirin against acute myocardial infarction and death in men with unstable angina: results of a Veterans Administration Cooperative Study. N Engl J Med 309:396PubMedGoogle Scholar
  25. Maree AO, Curtin RJ, Dooley M et al (2005) Platelet response to low-dose enteric-coated aspirin in patients with stable cardiovascular disease. J Am Coll Cardiol 46:1258–1263PubMedGoogle Scholar
  26. Marson P, Pasero G (2006) The Italian contributions to the history of salicylates. Reumatismo 58:66–75PubMedGoogle Scholar
  27. Mehta SR, Granger CB, Boden WE et al (2009) Early versus delayed invasive intervention in acute coronary syndromes. N Engl J Med 360:2165–2175, TIMACSPubMedGoogle Scholar
  28. Mueller C, Roskamm H, Neumann F-J et al (2003) A randomized comparison of clopidogrel and aspirin versus ticlopidine and aspirin after the placement of coronary artery stents. J Am Coll Cardiol 41:969–973PubMedGoogle Scholar
  29. Resnekov L, Chekiak J, Hirsh J et al (1989) Antithrombotic agents in coronary artery disease. Chest 95:528Google Scholar
  30. Sherman CT, Litrack F, Grundfest W et al (1986) Coronary angioscopy in patients with unstable angina pectoris. N Engl J Med 315:913PubMedGoogle Scholar
  31. Siller-Matula JM, Lang I, Christ G et al (2008) Calcium-channel blockers reduce the antiplatelet effect of clopidogrel. J Am Coll Cardiol 52:1557–1563PubMedGoogle Scholar
  32. Stone GW (2010) Ticagrelor in ACS: redefining a new standard of care? Lancet 375(9711):263–265PubMedGoogle Scholar
  33. Trenk D, Hochholzer W, Fromm MF et al (2008) Cytochrome P450 2C19 681G>A polymorphism and high-on clopidogrel platelet reactivity associated with adverse 1-year clinical outcome of elective percutaneous coronary intervention with drug-eluting or bare-metal stents. J Am Coll Cardiol 51:1925–1934PubMedGoogle Scholar
  34. Vainio H, Morgan G (1997) Aspirin for the second hundred years: new uses for an old drug. Pharmacol Toxicol 81:151–152PubMedGoogle Scholar
  35. Vane JN (1971) Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nat New Biol 231:232–235PubMedGoogle Scholar
  36. Wallentin L, Varenhorst C, James S et al (2008) Prasugrel achieves greater and faster P2Y12receptor-mediated platelet inhibition than clopidogrel due to more efficient generation of its active metabolite in aspirin-treated patients with coronary artery disease. Eur Heart J 29:21–30PubMedGoogle Scholar
  37. Wallentin L, Becker RC, Budaj A et al for the PLATO Investigators (2009) Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 361:1045–1057Google Scholar
  38. Wiviott SD, Trenk D, Frelinger AL et al (2007) Prasugrel compared with high loading- and maintenance-dose clopidogrel in patients with planned percutaneous coronary intervention: the Prasugrel in Comparison to Clopidogrel for Inhibition of Platelet Activation and Aggregation-Thrombolysis in Myocardial Infarction 44 trial. Circulation 116:2923–2932PubMedGoogle Scholar

Suggested Reading

  1. American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents, American Heart Association, Society for Cardiovascular Angiography and Interventions, Society of Thoracic Surgeons, Holmes DR Jr, Dehmer GJ, Kaul S, Leifer D, O'Gara PT, Michael Stein C (2010) ACCF/AHA Clopidogrel Clinical Alert: Approaches to the FDA “Boxed Warning.” J Am Coll CardiolGoogle Scholar
  2. Damani SB, Topol EJ (2010) The case for routine genotyping in dual-antiplatelet therapy. J Am Coll Cardiol. doi: 10.1016/j.jacc.2010.03.029Google Scholar
  3. Douketis JD et al (2008) The perioperative management of antithrombotic therapy: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 133:299–339Google Scholar
  4. Giugliano RP, Braunwald E (2009) The year in non-ST-segment elevation acute coronary syndrome. J Am Coll Cardiol 54:1544–1555PubMedGoogle Scholar
  5. Hochholzer W, Trenk D, Fromm MF et al (2010) Impact of cytochrome P450 2C19 loss-of-function polymorphism and of major demographic characteristics on residual platelet function after loading and maintenance treatment with clopidogrel in patients undergoing elective coronary stent placement. J Am Coll Cardiol 55:2427–2434PubMedGoogle Scholar
  6. Kushner FG, Hand M, Smith SC Jr et al (2009) 2009 Focused updates: ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction (updating the 2004 guideline and 2007 focused update) and ACC/AHA/SCAI guidelines on percutaneous coronary intervention (updating the 2005 guideline and 2007 focused update): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 54:2205–2241, Full TextPubMedGoogle Scholar
  7. Sørensen R, Hansen ML, Abildstrom SZ et al (2009) Risk of bleeding in patients with acute myocardial infarction treated with different combinations of aspirin, clopidogrel, and vitamin K antagonists in Denmark: a retrospective analysis of nationwide registry data. Lancet 374(6):1967–1974PubMedGoogle Scholar

Case Studies

  1. Aronow HD, Califf RM, Harrington RA et al (2008) Relation between aspirin dose, all-cause mortality, and bleeding in patients with recent cerebrovascular or coronary ischemic events. Am J Cardiol 102(10):1285–1290. BRAVO Trial InvestigatorsPubMedGoogle Scholar
  2. Bhat DL, Keith AA, Fox KAA et al (2006) Prevention of atherothrombotic events. N Engl J Med 354:1706–1717. CHARISMA InvestigatorsGoogle Scholar
  3. Cannon CP, Harrington RA, James S et al (2010) for the PLATelet inhibition and patient Outcomes (PLATO) investigators. Comparison of ticagrelor with clopidogrel in patients with a planned invasive strategy for acute coronary syndromes: a randomised double-blind study. Lancet 375(9711):283–293. PLATOGoogle Scholar
  4. CAPRIE Steering Committee (1996) A randomized, blinded, trial of clopidogrel versus aspirin in patients at risk of ischemic events. Lancet 348:1329. CAPRIEGoogle Scholar
  5. ClOpidogrel and Metoprolol in Myocardial Infarction Trial Collaborative Group (2005) Addition of clopidogrel to aspirin in 45, 852 patients with acute myocardial infarction: randomised placebo-controlled trial. Lancet 366:1607–1621. COMITT-2Google Scholar
  6. Diener H-C, Bogousslavsky J, Brass LM (2004) Aspirin and clopidogrel compared with clopidogrel alone after recent ischaemic stroke or transient ischaemic attack in high-risk patients: randomised, double-blind, placebo-controlled trial. Lancet 364:331–337. MATCHPubMedGoogle Scholar
  7. Mehta SR, Yusuf S, Peters RJ et al (2001) Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. Lancet 358:527–533. PCI-CUREPubMedGoogle Scholar
  8. Montalescot G, Wiviott SD, Braunwald E et al (2009) Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction (TRITON-TIMI 38): double-blind, randomised controlled trial. Lancet 373(9665):723–731. TRITON-TIMI 38 InvestigatorsPubMedGoogle Scholar
  9. O’Donoghue M, Antman EM, Braunwald E et al (2009) The efficacy and safety of prasugrel with and without a glycoprotein IIb/IIIa inhibitor in patients with acute coronary syndromes undergoing percutaneous intervention: a TRITON–TIMI 38 (Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition with Prasugrel-Thrombolysis in Myocardial Infarction 38) analysis. J Am Coll Cardiol 54:678–685. TRITON–TIMI 38PubMedGoogle Scholar
  10. Sabatine MS, Cannon CP, Gibson CM (2005) Effect of clopidogrel pretreatment before percutaneous coronary intervention in patients with ST-elevation myocardial infarction treated with fibrinolytics. JAMA 294:1224–1232. PCI-CLARITYPubMedGoogle Scholar
  11. Second International Study of Infarct Survival Collaborative Group (1988) Randomized trial of intravenous streptokinase, oral aspirin, both, or neither among 17, 187 cases of suspected acute myocardial infarction. Lancet 2:350. ISIS-2Google Scholar
  12. Steinhubl SR, Berger PB, Mann JT et al (2002) Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention. JAMA 288:2411. CREDOPubMedGoogle Scholar
  13. The Clopidogrel in Unstable Angina to Prevent Recurrent Events (2001) Effects of Clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST segment elevation. N Engl J Med 345:494–502. CUREGoogle Scholar
  14. The ESPRIT Study Group (2006) Aspirin plus dipyridamole versus aspirin alone after cerebral ischaemia of arterial origin (ESPRIT): randomised controlled trial. Lancet 367:1665–1673. ESPRITGoogle Scholar

Copyright information

© Springer Science+Business Media LLC 2011